Key result
Dipyridamole significantly reduces intravascular fibrin deposition and platelet consumption in preclinical models.
Why the study?
The mechanism by which dipyridamole inhibits intravascular fibrin deposition in vivo was not fully understood.
Does dipyridamole prevent intravascular fibrin deposition in rabbit models of induced thrombosis?
Does dipyridamole prevent intravascular fibrin deposition in rabbit models of induced thrombosis?
Answers are grounded in this paper and cite their sources.
Dipyridamole significantly inhibits intravascular fibrin deposition and platelet consumption in rabbit models, likely by inhibiting the precipitation of soluble fibrin monomer.
Intravascular fibrin deposition was induced in rabbits by endotoxin, the infusion of fibrin monomer (FM), and by the infusion of thrombin and EACA. A previously developed radioisotope technique was used to measure the fibrin deposits in various organs. Dipyridamole treatment of rabbits caused significant inhibition of fibrin deposition in all three experimental models. The drug also inhibited platelet consumption and, in the thrombin- and EACA-infused animals, fibrinogen consumption as well. The results obtained with dipyridamole were compared with the effect of thorotrast. It was concluded from this comparison that the effect of dipyridamole could not be attributed to inhibition of the reticuloendothelial system. It is postulated that dipyridamole inhibits the final step at which soluble FM is precipitated as fibrin in vivo.
No takes yet. Share an insight, caveat, or question.
Gurewich et al. (1975) studied Intravascular fibrin deposition. Dipyridamole vs. Thorotrast / Control was evaluated on Fibrin deposition in various organs. Dipyridamole treatment caused significant inhibition of intravascular fibrin deposition and platelet consumption in experimental rabbit models.
Synapse has enriched 10 related papers. Consider them for comparative context: